Regularly Scheduled Series Name

Course No. 25D12

Friday, April 18, 2025

8:00 am- 9:00 am

**\* \* \* ZOOM PRESENTATION \* \* \***

Join Zoom Meeting

<https://oklahoma.zoom.us/j/94156881405?pwd=dvucnptyObX7SZtIaadh1iX01eRqWc.1&from=addon>

|  |  |
| --- | --- |
| Meeting ID: | 941 5688 1405 |
| Passcode: | 28897140 |

**“Making Progress in the Treatment of Pancreatic Cancer”**

- - - - - - - - - - - - - - - - - - - -

Presented by:

**Philip Philip, MD, Ph.D., F.R.C.P**

**Chair, Hematology and Oncology**

**Leader, GI & Neuroendocrine Oncology**

**Professor of Oncology and Pharmacology**

**Co-Leader Pancreatic Cancer Program**

**Medical Director, Cancer Clinical and Translational Research Office**

**Chair, GI Cancer, SWOG**

**Henry Ford Cancer Institute**

**Wayne State University/Department of Oncology**

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™.*  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

The University of Oklahoma is an equal opportunity institution. [www.ou.edu/eoo](http://www.ou.edu/eoo)

**Accommodation Statement:** For accommodations, please contact Robin Vinson at (robin-vinson@ouhsc.edu).

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

**Disclosure & Mitigation Report**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | |  | |
| **Role(s)** | **First Name** | **Last Name** | **Ineligible Company** | **Nature of the Financial Relationship** |
| Planning Committee | Unaiza | Zaman, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Course Contact | Robin | Vinson | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Planning Member/Moderator | Naoko | Takebe, MD, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Course Director | Mohammad | Khawandanah | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Speaker | Philip | Philip, MD, PhD, FRCP | Novocure | Consulting Fee |
| Pfizer, Inc. | Advisor |
| Dr. Philip will be discussing experimental or off-label drug(s), device(s) and/or therapy(s) that have not been approved by the FDA. | | | | |